Option therapeutic approach for primary breast cancer

Abstract

Abstract. The first place in the ranking of oncology and the most acute oncology problem is breast cancer (BC), in the vast majority of women [1,2,3,5,18]. The rate of abstinence is high, and the percentage of patients receiving special therapy is 80.4%. All this indicates a low level of qualified care (Kolesnik O.O., Fedorenko Z.P., 2017). The aim of the study was the desire to study the effectiveness of various schemes of preoperative chemo-radiation therapy with radioimodification in the scheme of complex treatment of primary localized BC. Research results and their discussion. Analyzing 1 year of supervision, it is evident that 35 (83.3%) patients died in the I group, 7 died (16.7%). Patients who did not have a recurrence of the process at 1 year of life 25 (59.92%). In the II group, they died at 1 year - 6 (12.76%), and patients without relapsing 36 (76.59%). Comparing the result clearly that the overall survival of a reliable result was not low, and the rate of recurrence is likely to speak for the benefit of Group II. During second year , another 14 patients died in Group І against 7 group II. In the I survived, 21 (50,0%) were left, of which 17 (40,47%) without relapse were against 34 (72,34%) of the live ones, of which 20 (42,55%) without relapse. Summing up our research, supervision over the results of treatment in two groups, we can say that the remote survival results show the following: For 36 months. The observation formed the number of patients who clearly showed the results of treatment in groups I and II. In group І, overall survival rate was 11 (26,19%), with relapse 4 (9,52%). In the II group, the total number of patients with 3 years of observation was 25 (53,19%), with relapse of 17 (36,17%). Conclusions. The study of the effectiveness of the scheme of neoadjuvant chemo-therapy in combination with radiotherapy and radiomodification (group II) showed a positive trend in survival and relapse rates as well as a satisfactory state in the manifestations of toxicity of HT and radiation manifestations compared with the proposed scheme for group I.Изучение эффективности схемы неоад`ювантной химиотерапии в сочетании с лучевой терапией и радиомодификацией (II группа) выявило положительную тенденцию по показателям выживаемости и рецидивирования, а также удовлетворительное состояние в проявлениях токсичности ХТ и проявлений лучевых реакций в сравнении со схемой предложенной І группе. По результатам лечения в обеих группах, можно сказать, что отдаленные результаты выживаемости показывают следующее: на 36 мес. наблюдения: в первой группе общая выживаемость 11 (26,19%), из них с рецидивом 4 (9,52%). Во II группе общее количество больных на 3 год наблюдения 25 (53,19%), с рецидивом 17 (36,17%).